Home > Search Clinical Trials > Cancer - Female Reproductive

IRB No. U26-286-1 (Dr. Jennifer Jorgensen, PI): FRAmework-01: A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) versus Chemotherapy or Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer, and Sofetabart Mipitecan plus Bevacizumab versus Platinum-Based Chemotherapy plus Bevacizumab in Platinum-Sensitive Ovarian Cancer

The purpose of this research study is to learn more about sofetabart mipitecan also known as Sofe-M or LY4170156. Sofe-M is a new investigational drug under investigation in this study for the treatment of ovarian, primary peritoneal, or fallopian tube cancers.